AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11296544
Drug: NIM 200
RxNorm normalized name: L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-Nim-benzyl-histidyl-L-leucyl-L-arginyl-L-proline ethylamide
DrugBank: Histrelin (DB06788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NIM 200 mg/day
Trial: 11296544
Drug: NIM 400
RxNorm normalized name: L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-Nim-benzyl-histidyl-L-leucyl-L-arginyl-L-proline ethylamide
DrugBank: Histrelin (DB06788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NIM 400 mg/day
Trial: 11296544
Drug: NIM 100
RxNorm normalized name: L-pyroglutamyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-D-Nim-benzyl-histidyl-L-leucyl-L-arginyl-L-proline ethylamide
DrugBank: Histrelin (DB06788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: NIM 100 mg/day
Trial: 2956876
Drug: Enoximone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoximone (50 to 100 mg 3 times daily)
Trial: 27208905
Drug: Intravenous trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous trastuzumab (8 mg/kg loading, 6 mg/kg maintenance)
Trial: 18473286
Drug: Benfotiamine 600
RxNorm normalized name: BENFOTIAMINE
DrugBank: Benfotiamine (DB11748)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfotiamine 600 mg per day
Trial: 18473286
Drug: Benfotiamine 300
RxNorm normalized name: Benfotiamine 300mg Oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benfotiamine 300 mg per day
Trial: 8519722
Drug: Fentanyl (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (10 micrograms/mL)
Trial: 27128357
Drug: Mindfulness-Based Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-Based Cognitive Therapy (MBCT) plus Treatment as Usual (TAU)
Trial: 27128357
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Analysis System of Psychotherapy (CBASP) plus Treatment as Usual (TAU)
Trial: 24785463
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of both techniques
Trial: 15863798
Drug: Sibutramine (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sibutramine (up to 15 mg/day)
Trial: 12195728
Drug: Zinc supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zinc supplementation (25 mg orally for 3 months)
Trial: 12195728
Drug: Metoclopramide (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (5 mg intravenously)
Trial: 7727324
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose 1 mg morphine epidurally and continuous infusion of bupivacaine 0.75% + 0.2 mg/mL morphine at an infusion rate of 0.8 mL/hr
Trial: 7727324
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose 0.5 mg morphine epidurally and continuous infusion of bupivacaine 0.75% + 0.1 mg/mL morphine at an infusion rate of 0.8 mL/hr
Trial: 2109522
Drug: Tenoretic (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenoretic (100 mg atenolol + 25 mg chlorthalidone)
Trial: 2109522
Drug: Atenolol alone
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol alone (100 mg daily)
Trial: 2109522
Drug: Chlorthalidone alone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone alone (25 mg daily)
Trial: 2109522
Drug: Atenolol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (100 mg) plus Chlorthalidone (25 mg) taken separately
Trial: 6975811
Drug: Oral chloramphenicol
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral chloramphenicol (75 mg/kg/day)
Trial: 6975811
Drug: Intravenous chloramphenicol
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous chloramphenicol
Trial: 6975811
Drug: Oral chloramphenicol
RxNorm normalized name: Chloramphenicol
DrugBank: Chloramphenicol succinate (DB07565)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral chloramphenicol
Trial: 30990777
Drug: Porcine-based wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Porcine-based wound matrix dressing plus negative pressure wound therapy (NPWT)
Trial: 3074608
Drug: Flunarizine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunarizine (10 mg/day)
Trial: 28593473
Drug: Erenumab (AMG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erenumab (AMG 334); subcutaneous administration; pharmacokinetics characterized by a two-compartment target-mediated drug disposition model; absorption half-life of 1.6 days; bioavailability of 74%.
Trial: 25069999
Drug: Both therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both therapies (sclerotherapy and Nd:YAG laser)
Trial: 30954486
Drug: Uric acid
RxNorm normalized name: Uric acid
DrugBank: Uric acid (DB08844)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uric acid (UA) treatment
Trial: 15284771
Drug: Oral misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral misoprostol (100 mg every 4 hours up to 6 doses)
Trial: 15284771
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (administered by standardized protocol)
Trial: 11376176
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment within 12 hours of symptom onset
Trial: 9382054
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (mesalamine enema and mesalamine tablets)
Trial: 9382054
Drug: Mesalamine rectal
RxNorm normalized name: mesalamine Rectal Foam
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mesalamine rectal enema
Trial: 9382054
Drug: Oral mesalamine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral mesalamine tablets
Trial: 8257143
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) fluconazole, 100 mg, administered by constant-rate infusion over 30 min
Trial: 8257143
Drug: Oral (p.o.)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (p.o.) fluconazole, 100 mg
Trial: 8257143
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) fluconazole, 100 mg
Trial: 4085410
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg tiapride
Trial: 30082217
Drug: Intranasal arginine
RxNorm normalized name: Arginine
DrugBank: Arginine (DB00125)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal arginine vasopressin (AVP)
Trial: 24176199
Drug: Active Treatment
RxNorm normalized name: Active
DrugBank: Octisalate (DB11062)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active Treatment (AT, n=149)
Trial: 24176199
Drug: Delayed Treatment
RxNorm normalized name: GRANULES, DELAYED RELEASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed Treatment Control (DTC, n=130)
Trial: 20228458
Drug: Oral lycopene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lycopene 8 mg daily with radiotherapy
Trial: 15948817
Drug: NP-LS regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NP-LS regimen (prepackaged low-residue diet with LoSo Prep containing magnesium citrate, bisocodyl tablets, and bisocodyl suppository)
Trial: 15948817
Drug: 2F regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2F regimen (clear liquid diet with double-dose sodium phosphate)
Trial: 9177625
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg prolonged-release diclofenac sodium
Trial: 9177625
Drug: 3 enteric-coated
RxNorm normalized name: budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 3 enteric-coated tablets/day of 50 mg diclofenac sodium
Trial: 8191328
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg prostaglandin E2 (PGE2) gel extra‐amniotically
Trial: 8191328
Drug: 25 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg prostaglandin F2 alpha (PGF2 alpha) intra‐amniotically
Trial: 3546147
Drug: Ofloxacin 200
RxNorm normalized name: ofloxacin 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin 200 mg t.i.d. orally for ten days
Trial: 3546147
Drug: Amoxicillin 1
RxNorm normalized name: amoxicillin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 1 g t.i.d. orally for ten days
Trial: 23065358
Drug: No cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No cell therapy (controls)
Trial: 21392602
Drug: Autologous mesenchymal
RxNorm normalized name: AUTOLOGOUS MESENCHYMAL STROMAL CELLS SECRETING NEUROTROPHIC FACTORS
DrugBank: Debamestrocel (DB17934)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous mesenchymal stem cells (MSCs) administered transendocardially
Trial: 21392602
Drug: Whole bone
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole bone marrow mononuclear cells (BMCs) administered transendocardially
Trial: 15156256
Drug: Sulodexide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide treatment for 24 months after 6 months of oral anticoagulants.
Trial: 15156256
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no sulodexide treatment).
Trial: 15156256
Drug: Sulodexide treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulodexide treatment for 24 months.
Trial: 9256141
Drug: Dolasetron (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolasetron (2.4 mg/kg I.V. prechemotherapy, followed by 200 mg oral once daily for 6 days)
Trial: 9256141
Drug: Ondansetron (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (32 mg I.V. or 8 mg orally twice daily)
Trial: 9256141
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg I.V. followed by 8 mg oral once daily for 6 days) added to dolasetron
Trial: 9256141
Drug: Dexamethasone (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (8 mg I.V. followed by 8 mg oral once daily for 6 days) added to ondansetron
Trial: 8289411
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition through a subclavian venous catheter (group B)
Trial: 2941052
Drug: Diane (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diane (high dose cyproterone acetate with ethinyloestradiol)
Trial: 2941052
Drug: Minovlar (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minovlar (standard oestrogen and progestagen contraceptive pills)
Trial: 2941052
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose CPA
Trial: 27358493
Drug: TGF-β1 as
RxNorm normalized name: Anti-TGF-beta 2G7
DrugBank: 2G7 (DB18589)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGF-β1 as inhibitor of mitochondrial regulators and insulin signaling
Trial: 18451243
Drug: weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: weekly docetaxel
Trial: 16416385
Drug: Artemisinin-retinol combination
RxNorm normalized name: artemisinin
DrugBank: Artemisinin (DB13132)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artemisinin-retinol combination
Trial: 12574177
Drug: Risedronate 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 2.5 mg/d
Trial: 8912123
Drug: Omeprazole (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (40 mg daily; n = 20)
Trial: 8912123
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg twice daily; n = 18)
Trial: 26416147
Drug: Early BCG
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early BCG vaccine
Trial: 24628498
Drug: Escitalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (20 mg) after 2 weeks of open-label treatment
Trial: 24628498
Drug: Escitalopram (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (20 mg) titrated at Weeks 4 or 6
Trial: 24628498
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 mg for 12 weeks)
Trial: 21767239
Drug: HAART therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART therapy for 6 months
Trial: 21767239
Drug: HAART therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HAART therapy for 12 months
Trial: 19649993
Drug: Autologous bone
RxNorm normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous bone marrow cell (BMC) transplantation, intracoronary injection mean 7 days after STEMI
Trial: 15181616
Drug: t-TG/antigliadin antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: t-TG/antigliadin antibodies (AGA) stick
Trial: 12520747
Drug: Nedaplatin single
RxNorm normalized name: Nedaplatin
DrugBank: Nedaplatin (DB13145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nedaplatin single drug (100 mg/m2, i.v., every 3 weeks)
Trial: 9579495
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (2 mg bolus, followed by 125 microg/ml via PCA)
Trial: 9579495
Drug: Epidural fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Epidural fentanyl (100 microg bolus, followed by 25 microg/ml via PCA)
Trial: 7657965
Drug: Attapulgite (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attapulgite (600 mg tablets)
Trial: 2575766
Drug: suriclone (1.50‐2.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: suriclone (1.50‐2.25 mg/d)
Trial: 2575766
Drug: lorazepam (5.0‐7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lorazepam (5.0‐7.5 mg/d)
Trial: 865585
Drug: Conventional sunburn‐spectrum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional sunburn‐spectrum light in gradually increasing doses
Trial: 26065565
Drug: Selective COX-2
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selective COX-2 inhibitor (celecoxib)
Trial: 26065565
Drug: Nonsteroidal anti-inflammatory
RxNorm normalized name: Surpass Anti-Inflammatory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal anti-inflammatory drug (indomethacin)
Trial: 21872857
Drug: Intravenous tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous tranexamic acid (10 mg/kg)
Trial: 11022267
Drug: Rush Immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rush Immunotherapy (RIT)
Trial: 11022267
Drug: Conventional Immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Immunotherapy (CIT)
Trial: 1350686
Drug: Vecuronium (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.05 mg/kg)
Trial: 1350686
Drug: Atracurium (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.25 mg/kg)
Trial: 30048574
Drug: No endocrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No endocrine therapy for ER+ DCIS
Trial: 25439407
Drug: Propofol 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 0.6 mg/kg + Ketamine 0.8 mg/kg + Midazolam 0.06 mg/kg (three-drug group)
Trial: 25439407
Drug: Etomidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate 0.3 mg/kg (single-drug group)
Trial: 19176733
Drug: green tea-caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: green tea-caffeine mixture (270 mg epigallocatechin gallate + 150 mg caffeine/d) with adequate protein (AP) diet (50-60 g protein/d)
Trial: 19176733
Drug: green tea-caffeine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: green tea-caffeine mixture (270 mg epigallocatechin gallate + 150 mg caffeine/d) with high-protein (HP) diet (100-120 g protein/d)
Trial: 19176733
Drug: adequate protein
RxNorm normalized name: protein C
DrugBank: Protein C (DB11312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adequate protein (AP) diet (50-60 g protein/d) + placebo
Trial: 11207837
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received identical physiotherapeutic treatment 2 times a week, excluding strengthening and balance training
Trial: 7999459
Drug: Estrogen-replacement therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen-replacement therapy (ERT) with Premarin at 0.625 mg, days 1-25
Trial: 29249584
Drug: UFT/LV (300-600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT/LV (300-600 mg/d UFT with 75 mg/d LV on days 1-28, every 35 days, for 5 cycles)
Trial: 29249584
Drug: SOX (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOX (100 mg/m2 of oxaliplatin on day 1 with 80-120 mg/d S-1 on days 1-14, every 21 days, for 8 cycles)
Trial: 28797414
Drug: Low transaortic
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low transaortic flow rate (FR) defined as <200 ml/s
Trial: 23921143
Drug: Erythropoiesis-stimulating agent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoiesis-stimulating agent (ESA)
Trial: 17853395
Drug: Gabapentin (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (target dose, 2700 mg) for 6 weeks
Trial: 9696975
Drug: No preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No preoperative intestinal preparation (n = 53)
Trial: 1095964
Drug: S-adenosylmethionine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-adenosylmethionine (150 mg daily) and vitamin B-12 (2000 gamma)
Trial: 29730393
Drug: Traditional graded
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional graded activity or graded exposure therapies
Trial: 26279073
Drug: 200 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 µg chromium picolinate supplements
Trial: 24179293
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light (∼3000 lux, ∼7 Watts/m(2)) + melatonin (5 mg)
Trial: 24179293
Drug: Dim light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dim light (∼1.9 lux, ∼0.6 Watts/m(2)) + melatonin (5 mg)
Trial: 18805524
Drug: Isosorbide mononitrate
RxNorm normalized name: Isosorbide Mononitrate
DrugBank: Isosorbide mononitrate (DB01020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide mononitrate (20 mg daily)
Trial: 9886891
Drug: orlistat 120
RxNorm normalized name: orlistat 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: orlistat 120 mg three times a day (tid)
Trial: 7987364
Drug: Midluteal phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midluteal phase (ML) at 35% intensity
Trial: 7987364
Drug: Midluteal phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midluteal phase (ML) at 60% intensity
Trial: 7987364
Drug: Midluteal phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Midluteal phase (ML) at 75% intensity
Trial: 2736696
Drug: Li Dan
RxNorm normalized name: LIS-1
DrugBank: LIS-1 (DB18388)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Li Dan Ling treatment group
Trial: 1098726
Drug: Peroperative intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peroperative intermittent calf compression with low-dose heparin
Trial: 1098726
Drug: Peroperative intermittent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peroperative intermittent calf compression without low-dose heparin (control)
Trial: 24431394
Drug: Certolizumab pegol
RxNorm normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Certolizumab pegol (CZP) 400 mg at weeks 0, 2, and 4, then 200 mg every 2 weeks
Trial: 19825777
Drug: Minimally invasive
RxNorm normalized name: SPY Minimally Invasive Surgery (SPY-MIS) Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimally invasive surgery with functional after-treatment
Trial: 19825777
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment by functional bracing
Trial: 15388005
Drug: Toremifene plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toremifene plus MVP chemotherapy (mitomycin, vindesin, and cisplatin)